SHORTEN-2 trial
LightNews LightNews
banner
shorten2trial.bsky.social
SHORTEN-2 trial
@shorten2trial.bsky.social
800 followers 1.1K following 22 posts
RCT 7 vs 14 days of treatment for P. aeruginosa BSI.
Updated trial progress and #FOAMed on P. aeruginosa.
#AMSSky #IDSky #PsWatch
Powered by @guiaprioam.bsky.social

📚 Full protocol: https://shorturl.at/xN0wj
🌐 https://clinicaltrials.gov/study/NCT05210439
Posts Replies Media Videos
Reposted by SHORTEN-2 trial
josemolinagb.bsky.social
It’s encouraging to see new guidelines moving toward shorter and fully-oral treatments for BSIs.

We are honoured to see some of our research cited to help shape these recommendations! 😃

#AMSsky #IDsky #UTIsky @hospitaluvrocio.bsky.social @ibis-investigacion.bsky.social bsky.app/profile/jose...
josemolinagb.bsky.social José Molina @josemolinagb.bsky.social · Nov 12
Can we treat patients with low-risk BSI discharged from the ED with a fully-oral course of antibiotics?

[Spoiler: Yes!]

🆓🔓Our recent article on #OralIsTheNewIV! 👉🏻 journals.asm.org/doi/10.1128/...

Food for thought for #AMSsky #IDSky
Safety of early oral ambulatory treatment of adult patients with bloodstream infections discharged from the emergency department | Antimicrobial Agents and Chemotherapy
Randomized trials have unanimously shown the benefits of oral antibiotic treatments for stable patients with bacteremia (1). However, transition to oral therapy has been usually performed after several days of intravenous treatment—frequently up to 7 days (2)—highlighting the need for evidence of the safety of earlier oral treatments (3).
journals.asm.org
July 19, 2025 at 9:00 AM
shorten2trial.bsky.social
This is a classic review on Pseudomonas:
journals.asm.org/doi/epub/10....

And here you’ll find some more recent data on resistance against new betalactams:
www.sciencedirect.com/science/arti...

Hope you find it useful! #PsWatch #IDsky
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
journals.asm.org
May 3, 2025 at 11:13 PM
shorten2trial.bsky.social
In SHORTEN-2, immunocompromised hosts were not excluded if early clinical response and no unresolved source issues exist at randomization.
We hope to generate actionable data to guide the management of Pseudomonas BSI also in this population! 💪🏼
(🧵3/3) #AMSky #IDsky #TxID #IDOnc #ShorterIsBetter
April 29, 2025 at 10:29 PM
shorten2trial.bsky.social
We have evidence from several observational studies that show how, if adequately selected, uncomplicated infections may be safely treated with shorter courses, even in severely immunocompromised hosts like SOT or neutropenic patients.
(🧵2/3) #AMSky #IDsky #TxID #IDOnc

bsky.app/profile/jose...
josemolinagb.bsky.social José Molina @josemolinagb.bsky.social · Nov 19
#ShorterIsBetter in immunocompromised hosts?
Short treatments are feasible in early responders without source control issues.

A significant number of observational studies serve as proof-of-concept on the feasibility of short courses in selected patients (see ⚠️)

#AMSsky #IDOnc #TxID #IDsky
A summary table on published observational studies on treatment duration of bloodstream infections in hematology patients with high-risk neutropenia. References: doi: 10.1007/s10096-024-04885-w doi: 10.1111/tid.14085 doi: 10.1016/j.jinf.2021.10.017 doi: 10.1093/cid/ciad605 doi: 10.1093/ofid/ofaa246 A summary table on published observational studies on treatment duration of graft infections on solid-organ transplant recipients. References: doi: 10.1111/tid.13896 doi: 10.1111/tri.14144 doi: 10.1111/tid.13868 doi: 10.1111/tid.13518
April 29, 2025 at 10:16 PM
Reposted by SHORTEN-2 trial
listeriacolectiva.bsky.social
6/ Además, hablamos de SHORTEN2, un estudio que dará mucho que hablar próximamente. 🔜📊

t.co/5whVazbnTo
https://pmc.ncbi.nlm.nih.gov/articles/PMC9778939/
t.co
February 15, 2025 at 7:31 PM